These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22840667)

  • 1. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D
    Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethics and eplerenone.
    Gupta S; Fugh-Berman AJ; Scialli A
    J Med Ethics; 2013 Feb; 39(2):110-4. PubMed ID: 23015747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
    Frankenstein L; Seide S; Täger T; Jensen K; Fröhlich H; Clark AL; Seiz M; Katus HA; Nee P; Uhlmann L; Naci H; Atar D
    Heart Fail Rev; 2020 Mar; 25(2):161-171. PubMed ID: 31364027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR; Tang WH; Francis GS
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):368-78. PubMed ID: 17589427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
    Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.